A single‐arm, open‐label study of alemtuzumab in treatment‐refractory patients with multiple sclerosis

Abstract

Alemtuzumab effectively reduced relapse rates and improved clinical scores in patients with active relapsing-remitting multiple sclerosis not controlled by interferon therapy.